Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349245 · ClinicalTrials.gov registry record · Phase 4
Dexmedetomidine vs. Remifentanil for Sedation During AFI
A Phase 4 study of Intubation, Endotracheal, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00349245 is a Phase 4 study of Intubation, Endotracheal that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00349245, a Phase 4 study of Intubation, Endotracheal, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for ICU and intraoperative sedation as a sedative during awake fiberoptic intubation, as compared to Remifentanil. The hypothesis is that Dexmedetomidine will provide at least equal if not better conditions (sedation and analgesia) required for awake fiberoptic intubation (Ramsay Sedation Scale 3) with less respiratory and cardiovascular adverse effects, as well as less recall than Remifentanil.
Conditions Studied
Interventions
- DRUG Dexmedetomidine
- DRUG Remifentanil
Study Locations (1)
Texas
- Memorial Hermann Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349245
The ClinicalTrials.gov registry entry for NCT00349245 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intubation, Endotracheal appearing as the primary indexed condition, and to 2 interventions - of which Dexmedetomidine is the first listed.
NCT00349245 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00349245 about?
NCT00349245 is a clinical study titled "Dexmedetomidine vs. Remifentanil for Sedation During AFI". The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for ICU and intraoperative sedation as a sedative during awake fiberoptic intubation, as compared to Remifentanil. The hyp...
What is the current status of trial NCT00349245?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-06. Estimated completion is 2007-08.
What conditions does trial NCT00349245 study?
This clinical trial studies the following conditions: Intubation, Endotracheal.
What interventions are being tested in trial NCT00349245?
The interventions under investigation include: Dexmedetomidine (DRUG), Remifentanil (DRUG).
Who is sponsoring clinical trial NCT00349245?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00349245 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intubation, Endotracheal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.